In vitro testing of thiolated poly(aspartic acid) from ophthalmic formulation aspects

References

• Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 2005;57:1595–639.
   PubMed Web of Science ®Google Scholar
• Lorentz H, Sheardown H. Ocular delivery of biopharmaceuticals. In: Neves J, Sarmento B, eds. Mucosal delivery of biopharmaceuticals: biology, challenges and strategies. New York (NY): Springer; 2014:221–59.
   Google Scholar
• Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006;58:1131–5.
   PubMed Web of Science ®Google Scholar
• Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv 2006;3:275–87.
   PubMed Web of Science ®Google Scholar
• Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol 1993;37:435–56.
   PubMed Web of Science ®Google Scholar
• Baeyens V, Gurny R. Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations. Pharm Acta Helv 1997;72:191–202.
   PubMedGoogle Scholar
• Gavini E, Bonferoni MC, Rassu G, et al. Engineered microparticles based on drug-polymer coprecipitates for ocular-controlled delivery of Ciprofloxacin: influence of technological parameters. Drug Dev Ind Pharm 2015 [Epub ahead of print]. doi: 10.3109/03639045.2015.1100201.
   PubMed Web of Science ®Google Scholar
• Üstündağ-Okur N, Gökçe EH, Bozbıyık DI, et al. Novel nanostructured lipid carrier-based inserts for controlled ocular drug delivery: evaluation of corneal bioavailability and treatment efficacy in bacterial keratitis. Expert Opin Drug Deliv 2015;12:1791–807.
   PubMed Web of Science ®Google Scholar
• Fabiano A, Chetoni P, Zambito Y. Mucoadhesive nano-sized supramolecular assemblies for improved pre-corneal drug residence time. Drug Dev Ind Pharm 2015;41:2069–76.
   PubMed Web of Science ®Google Scholar
• Nasr FH, Khoee S. Design, characterization and in vitro evaluation of novel shell crosslinked poly(butylene adipate)-co-N-succinyl chitosan nanogels containing loteprednol etabonate: a new system for therapeutic effect enhancement via controlled drug delivery. Eur J Med Chem 2015;102:132–42.
   PubMed Web of Science ®Google Scholar
• Chhonker YS, Prasad YD, Chandasana H, et al. Amphotericin-B entrapped lecithin/chitosan nanoparticles for prolonged ocular application. Int J Biol Macromol 2015;72:1451–8.
   PubMed Web of Science ®Google Scholar
• Horvát G, Budai-Szű cs M, Berkó S, et al. Comparative study of nanosized cross-linked sodium-, linear sodium- and zinc-hyaluronate as potential ocular mucoadhesive drug delivery systems. Int J Pharm 2015;494:321–8.
   PubMed Web of Science ®Google Scholar
• Fernández-Ferreiro A, González Barcia M, Gil-Martínez M, et al. In vitro and in vivo ocular safety and eye surface permanence determination by direct and Magnetic Resonance Imaging of ion-sensitive hydrogels based on gellan gum and kappa-carrageenan. Eur J Pharm Biopharm 2015;94:342–51.
   PubMed Web of Science ®Google Scholar
• Abdelkader H, Pierscionek B, Alany RG. Novel in situ gelling ocular films for the opioid growth factor-receptor antagonist-naltrexone hydrochloride: fabrication, mechanical properties, mucoadhesion, tolerability and stability studies. Int J Pharm 2014;477:631–42.
   PubMed Web of Science ®Google Scholar
• Makwana SB, Patel VA, Parmar SJ. Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride. Results Pharma Sci. [Epub ahead of print]. doi:10.1016/j.rinphs.2015.06.001.
   PubMedGoogle Scholar
• Horvát G, Gyarmati B, Berkó S, et al. Thiolated poly(aspartic acid) as potential in situ gelling, ocular mucoadhesive drug delivery system. Eur J Pharm Sci 2015;67:1–11.
   PubMed Web of Science ®Google Scholar
• Ahmed I, Gokhale RD, Shah MV, Patton TF. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. J Pharm Sci 1987;76:583–6.
   PubMed Web of Science ®Google Scholar
• Sasaki H, Igarashi Y, Nagano T, et al. Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic beta-blockers. Pharm Res 1995;12:1146–50.
   PubMed Web of Science ®Google Scholar
• Rabinovich-Guilatt L, Couvreur P, Lambert G, Dubernet C. Cationic vectors in ocular drug delivery. J Drug Target 2004;12:623–33.
   PubMed Web of Science ®Google Scholar
• Sunkara G, Kompella UB. Membrane transport processes in the eye. In: Mitra AK, ed. Ophthalmic drug delivery systems. New York (NY): Marcel Dekker Inc.; 2003:13–58.
   Google Scholar
• Mahmood A, Bonengel S, Laffleur F, et al. Can thiolation render a low molecular weight polymer of just 20-kDa mucoadhesive? Drug Dev Ind Pharm 2015. [Epub ahead of print]. DOI: 10.3109/03639045.2015.1061538.
   PubMed Web of Science ®Google Scholar
• Shell JW. Pharmacokinetics of topically applied ophthalmic drugs. Surv Ophthalmol 1982;26:207–18.
   PubMed Web of Science ®Google Scholar
• ASHP technical assistance bulletin on pharmacy-prepared ophthalmic products. American Society of Hospital Pharmacists. Am J Hosp Pharm 1993;50:1462–3.
   PubMedGoogle Scholar
• Ali Y, Lehmussaari K. Industrial perspective in ocular drug delivery. Adv Drug Deliv Rev 2006;58:1258–68.
   PubMed Web of Science ®Google Scholar
• DB-ALM, MTT Assay-Summary Method. Available from: http://ecvam-dbalm.jrc.ec.europa.eu/ [last accessed 26 Aug 2015].
   Google Scholar
• Almeida H, Amaral MH, Lobão P, Lobo JM. In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov Today 2014;19:400–12.
   PubMed Web of Science ®Google Scholar
• Gyarmati B, Vajna B, Némethy Á, et al. Redox- and pH-responsive cysteamine-modified poly(aspartic acid) showing a reversible sol-gel transition. Macromol Biosci 2013;13:633–40.
   PubMed Web of Science ®Google Scholar
• Gyarmati B, Krisch E, Szilágyi A. In situ oxidation-induced gelation of poly(aspartic acid) thiomers. React Funct Polym 2014;84:29–36.
   Web of Science ®Google Scholar
• Operating manual OCA (OCA 5, OCA 10, OCA 15, OCA 15 plus, OCA 20, OCA 30, OCAH 200 and OCAH 230) Dataphysics (2002) 71.
   Google Scholar
• Sandri G, Bonferoni MC, Rossi S, et al. Thermosensitive eyedrops containing platelet lysate for the treatment of corneal ulcers. Int J Pharm 2012;426:1–6.
   PubMed Web of Science ®Google Scholar
• Mori M, Rossi S, Bonferoni MC, et al. Calcium alginate particles for the combined delivery of platelet lysate and vancomycin hydrochloride in chronic skin ulcers. Int J Pharm 2014;461:505–13.
   PubMed Web of Science ®Google Scholar
• Salcedo I, Sandri G, Aguzzi C, et al. Intestinal permeability of oxytetracycline from chitosan-montmorillonite nanocomposites. Colloids Surf B Biointerfaces 2014;117:441–8.
   PubMed Web of Science ®Google Scholar
• Patel S, Boyd KE, Burns J. Age, stability of the precorneal tear film and the refractive index of tears. Cont Lens Anterior Eye 2000;23:44–7.
   PubMedGoogle Scholar
• Yañez-Soto B, Mannis MJ, Schwab IR, et al. Interfacial phenomena and the ocular surface. Ocul Surf 2014;12:178–201.
   PubMed Web of Science ®Google Scholar
• Ziemssen F, Zierhut M. Principles of therapy. In: Fraunfelder FT, Fraunfelder FW, Chambers WA, eds. Clinical ocular toxicology. Drugs, chemicals and herbs. Philadelphia (PA): Saunders Elsevier; 2008:1–7.
   Google Scholar
• Januleviciene I, Siaudvytyte L, Barsauskaite R. Ophthalmic drug delivery in glaucoma – a review. Pharmaceutics 2012;4:243–51.
   PubMedGoogle Scholar
• Pallas NR, Harrison Y. An automated drop shape apparatus and the surface tension of pure water. Colloids Surf 1990;43:169–94.
   Google Scholar
• Taylor S, Galbraith SM, Mills RP. Causes of non-compliance with drug regimens in glaucoma patients: a qualitative study. J Ocul Pharmacol Ther 2002;18:401–9.
   PubMed Web of Science ®Google Scholar
• Lafuma A, Robert J, Berdeaux G. Ocular discomfort, compliance and intra-ocular pressure (IOP) control in patients treated for glaucoma. Value Health 2011;14:A502 (IGR:13-4).
   Google Scholar
• Fraunfelder FT. Ocular drug delivery and toxicology. In: Fraunfelder FT, Fraunfelder FW, Chambers WA, eds. Clinical ocular toxicology. Drugs, chemicals and herbs. Philadelphia (PA): Saunders Elsevier; 2008:9–14.
   Google Scholar
• Vian L, Vincent J, Maurin J, et al. Comparison of three in vitro cytotoxicity assays for estimating surfactant ocular irritation. Toxicol In Vitro 1995;9:185–90.
   PubMed Web of Science ®Google Scholar
• Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm 2009;71:505–18.
   PubMed Web of Science ®Google Scholar
• Saettone MF, Giannaccini B, Guiducci A, et al. Polymer effects on ocular bioavailability. II. The influence of benzalkonium chloride on the mydriatic response of tropicamide in different polymeric vehicles. Int J Pharm 1985;25:73–83.
   Web of Science ®Google Scholar
• Asane GS, Nirmal SA, Rasal KB, et al. Polymers for mucoadhesive drug delivery system: a current status. Drug Dev Ind Pharm 2008;34:1246–66.
   PubMed Web of Science ®Google Scholar
• Millotti G, Vetter A, Leithner K, et al. Development of thiolated poly(acrylic acid) microparticles for the nasal administration of exenatide. Drug Dev Ind Pharm 2014;40:1677–82.
   PubMed Web of Science ®Google Scholar
• Robinson JR, Mlynek GM. Bioadhesive and phase-change polymers for ocular drug delivery. Adv Drug Deliv Rev 1995;16:45–50.
   Web of Science ®Google Scholar